G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
114 hedge funds and large institutions have $541M invested in G1 Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 20 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
12% more call options, than puts
Call options by funds: $7.08M | Put options by funds: $6.33M
7% less capital invested
Capital invested by funds: $582M → $541M (-$40.3M)
7% less funds holding
Funds holding: 123 → 114 (-9)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$20.3M |
| 2 |
Morgan Stanley
New York
|
+$7.46M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.55M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$5.17M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.1M |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$14.5M |
| 3 |
Two Sigma Investments
New York
|
-$4.7M |
| 4 |
Goldman Sachs
New York
|
-$2.86M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$2.55M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
126
Abbot Financial Management
Andover,
Massachusetts
| – | -$208K | -8,650 | Closed |
|
127
Pacer Advisors
Malvern,
Pennsylvania
| – | -$81K | -3,366 | Closed |
|
|
SFS
128
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$47K | -2,381 | Closed |
|
129
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$28K | -1,107 | Closed |
|
|
SPIA
130
Steward Partners Investment Advisory
New York
| – | -$24.1K | -1,000 | Closed |
|
|
HIA
131
Harbor Investment Advisory
Lutherville,
Maryland
| – | -$6K | -250 | Closed |
|
|
JCM
132
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$6K | -250 | Closed |
|
|
WP
133
WealthShield Partners
Cary,
North Carolina
| – | -$5K | -208 | Closed |
|
|
RFA
134
Reilly Financial Advisors
La Mesa,
California
| – | -$5K | -200 | Closed |
|
GTHX Hedge Fund Activity: Q2 2021 in Review
114 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2021, worth a combined $541M — down 6.9% from $582M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of GTHX and 11 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 43 added.
The largest buyer was Fisher Asset Management, opening a new position worth an estimated $20.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.1M.
- 114 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2021, down from 123 in Q1 2021.
- Funds reported $541M of G1 Therapeutics, Inc. Common Stock stock for Q2 2021, down 6.9% quarter-over-quarter.
- 11 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2021 and 20 closed out, a net change of -9 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2021 was Fisher Asset Management, an estimated $20.3M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2021 was T. Rowe Price Associates, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2021.